Efficacy of Yangxue Qingnao Granule on Alzheimer's Disease and Effect on VEGF Level

Li HUANG; Linhong MO; Aixian LIU

doi:10.13422/j.cnki.syfjx.20221327

您当前的位置：

首页 >

文章列表页 >

Efficacy of Yangxue Qingnao Granule on Alzheimer's Disease and Effect on VEGF Level

更新时间：2022-09-01

- Efficacy of Yangxue Qingnao Granule on Alzheimer's Disease and Effect on VEGF Level
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 28, Issue 14, Pages: 121-126(2022)
- 作者机构：
  
  首都医科大学附属北京康复医院，北京 100144
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20221327
  CLC： R22;R242;R2-031;R287
- Published：20 July 2022，
  
  Published Online：19 April 2022，
  
  Received：21 February 2022，
- 稿件说明：
扫描看全文
黄丽,莫林宏,刘爱贤.养血清脑颗粒治疗阿尔茨海默病的疗效及对血管内皮生长因子的影响[J].中国实验方剂学杂志,2022,28(14):121-126.

HUANG Li,MO Linhong,LIU Aixian.Efficacy of Yangxue Qingnao Granule on Alzheimer's Disease and Effect on VEGF Level[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(14):121-126.
黄丽,莫林宏,刘爱贤.养血清脑颗粒治疗阿尔茨海默病的疗效及对血管内皮生长因子的影响[J].中国实验方剂学杂志,2022,28(14):121-126. DOI： 10.13422/j.cnki.syfjx.20221327.

HUANG Li,MO Linhong,LIU Aixian.Efficacy of Yangxue Qingnao Granule on Alzheimer's Disease and Effect on VEGF Level[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(14):121-126. DOI： 10.13422/j.cnki.syfjx.20221327.

摘要

目的

观察阿尔茨海默病（AD）患者血清中血管内皮生长因子（VEGF）的含量变化，探讨养血清脑颗粒治疗AD的疗效及对VEGF的影响。

方法

选择60例认知障碍患者，其中遗忘型轻度认知障碍（aMCI）及AD患者各30例；健康对照组30例为同期门诊收集的健康人员，蒙特利尔认知评估量表（MoCA）≥26分，年龄、性别及并发症情况与患者组比较差异无统计学意义。入组时，给予aMCI组、AD组及健康对照组静脉抽血，测定血清VEGF水平。再将aMCI患者及AD患者按照随机信封法分为对照组和观察组，两组均给予常规西医治疗（盐酸多奈哌齐5 mg·d

-1

），观察组同时给予养血清脑颗粒口服治疗。治疗6个月后，比较对照组和观察组患者的临床疗效、认知量表评分及不良反应，再次静脉抽血检测治疗前后两组患者VEGF的变化情况。

结果

AD痴呆患者血清中VEGF含量明显低于aMCI患者及健康对照组（

0.05）；aMCI患者血清VEGF水平也明显低于健康对照组（

0.05）。经治疗后，观察组患者血清VEGF水平较本组治疗前明显升高（

0.05），且明显高于对照组VEGF水平（

0.05）；以MoCA评估患者认知障碍程度，观察组患者的认知功能改善情况优于对照组，观察组治疗总有效率高于对照组（

0.05），观察组经治疗后MoCA评分明显升高（

0.05），且明显高于对照组（

0.05）。观察组不良反应发生率与对照组比较差异无统计学意义。

结论

AD痴呆患者血清中VEGF水平明显下降，aMCI患者血清中VEGF也明显下降，提示血管生成机制参与了AD的病理生理过程，且与AD发病早期阶段相关。养血清脑颗粒辅助治疗aMCI及AD痴呆患者具有较好的临床疗效，可有效改善认知功能，其机制可能与提高VEGF水平，促进血管生成，改善脑皮层微循环有关，且具有良好的安全性。

Abstract

Objective

To observe the variation in content of vascular endothelial growth factor （VEGF） in patients with Alzheimer's disease （AD） and to investigate efficacy of Yangxue Qingnao granule on AD and the effect on VEGF.

Method

A total of 60 patients with cognitive impairment ［30 of AD and 30 of amnestic mild cognitive impairment （aMCI）］ were selected， and another 30 healthy people with Montreal Cognitive Assessment （MoCA）≥26 and age， gender， and complications insignificantly different from the patients were included as healthy control. The venous blood of aMCI group， AD group， and the healthy control group was collected at the enrollment to measure the level of serum VEGF. Then， the aMCI and AD patients were randomized into the observation group and the control group， with 30 patients in each group. The control group was given Donepezil Hydrochloride （5 mg·d

-1

）， while the observation group received Donepezil Hydrochloride （5 mg·d

-1

） and Yangxue Qingnao granule. MoCA was used to evaluate the severity of cognitive impairment. After the treatment for 6 months， the clinical efficacy and adverse reactions of the two groups were compared， and the serum VEGF levels were detected again by enzyme-linked immunosorbent assay （ELISA）.

Result

The serum content of VEGF in AD patients was significantly lower than that in aMCI patients and healthy people （

0.05）. Serum VEGF levels in aMCI patients were significantly decreased compared with those in healthy people （

0.05）. After treatment for 6 months， the serum VEGF level in the observation group was significantly higher than that before treatment， and was higher than that in the control group （

0.05）. MoCA scores in the observation group were higher than those in control group （

0.05）. The incidence of adverse reactions was insignificantly different between both groups.

Conclusion

The serum levels of VEGF significantly decreased in aMCI and AD patients， suggesting that angiogenesis might be involved in the pathophysiological process of AD and correlated with the early stage of AD. Yangxue Qingnao granule， as a safe adjuvant therapy， showed ideal effect on aMCI and AD， as manifested by the improvement of cognitive function. The mechanism is the likelihood that it can elevate the expression of angiogenic factors such as VEGF， promote angiogenesis， and then improve the microcirculation of cortex.

关键词

阿尔茨海默病（AD）轻度认知障碍痴呆血管内皮生长因子血管生成养血清脑颗粒

Keywords

Alzheimer's diseasemild cognitive impairmentdementiavascular endothelial growth factor （VEGF）angiogenesisYangxue Qingnao granule

references

BALLARD C， GAUTHIER S， CORBETT A， et al. Alzheimer's disease［J］. Lancet， 2011， 377（9770）： 1019-1031.

MCKHANN G M， KNOPMAN D S， CHERTKOW H， et a1. The diagnosis of dementia due to A1zheimer's disease： Recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease ［J］. Alzheimers Dement， 2011， 7（3）： 263-269.

KUA E H， HO E， TAN H H， et al. The natural history of dementia ［J］. Psychogeriatrics， 2014， 14（3）： 196.

JIA L F， DU Y F， CHU L， et al. Prevalence， risk factors， and management of demantia and mild cognitive impairment in adults aged 60 years or older in China： A cross-sectional study［J］. Lancet Public Health， 2020， 5（12）： E661-E671.

贾建平，侯婷婷.阿尔茨海默病发病机制及治疗进展［J］.中华医学杂志，2018， 98（29）：2351-2356.

SNYDER H M， CORRIVEAU R A， CRAFT S， et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease［J］. Alzheimers Dement，2015， 11（6）： 710-717.

VAGNUCCI A H， LI W W. Alzheimer's disease and angiogenesis［J］. Lancet， 2003， 361 （9357）： 605-608.

张伯礼，薛博.中医内科学［M］.北京：人民卫生出版社，2012：122-128.

SHI J， TIAN J Z， LONG Z Y， et al. The patten element scale： A brief tool of traditional medical subtyping for dementia［J］. Evid Based complement Alternat Med， 2013， 2013 （2）： 460-562.

夏冬琴，李荣亨.养血清脑颗粒在神经系统疾病治疗中的应用研究进展［J］. 实用中医药杂志，2017，33（10）：1228-1230.

TUCKER G J．精神障碍诊断与统计手册［M］．5版．北京：北京大学出版社，2013：614-618.

ARTERO S， PETERSEN R， TOUCHON J， et al. Revised criteria for mild cognitive impairment： validation within a longitudinal population study［J］. Dement Geriatr Cogn Disord ， 2006， 22 （5/6）： 465-470.

PETERSEN R C. Mild cognitive impairment as a diagnostic entity［J］. J Intern Med， 2004， 256 （3）： 183-194.

国家中医药管理局医政司.24个专业104个病种中医诊疗方案［M］.北京：国家中医药管理局医政司，2012： 540-548．

田金洲，时晶．阿尔茨海默病的中医诊疗共识［J］.中国中西医结合杂志，2018，38（5）： 523-529．

国家中医药管理局.中医临床诊疗术语第2部分：证候（修订版）［M］.北京：国家中医药管理局，2020.

NASREDDINE Z S， PHILLIPS N A， BEDIRIAN V， et al. The montreal cognitive assessment， MoCA： A brief screening tool for mild cognitive impairment ［J］， J Am Geriatr Soc， 2005， 53 （4）： 695-699.

ROTHWELL P M， PENDLEBURY S T， MEHTA Z， et al. MoCA， ACE-R， and MMSE versus the national institute of neurological disorders and stroke-canadian stroke network vascular cognitive impairment harmonization standards neuropsychological battery after TIA and stroke ［J］. Stroke， 2018， 43 （2）： 464-469．

PIMENTEL-COELHO P M， RIVEST S. The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer's disease ［J］. Eur J Neurosci， 2012， 35 （12）：1917-1937.

DING B， LING H W， ZHANG Y， et al. Pattern of cerebral hyperperfusion in Alzheimer's disease and amnestic mild cognitive impairment using voxel-based analysis of 3D arterial spin-labeling imaging： Initial experience ［J］. Clin Interv Aging， 2014， 9 （3）： 493-500.

THAL D R， ATTEMS J， EWERS M. Spreading of amyloid， tau， and microvascular pathology in Alzheimer's disease： Findings from neuropathological and neuroimaging studies ［J］. J Alzheimers Dis， 2014， 42（Suppl 4）： S421-429.

FERRARA N， GERBER H P， LECOUTER J. The biology of VEGF and its receptors［J］. Nat Med， 2003， 9 （6）： 669-676.

GREENBERG D A， JIN K. VEGF and ALS： The luckiest growth factor？［J］. Trends Mol Med， 2004， 10 （1）： 1-3.

YANG S P， BAE D G， KANG H J， et al. Coaccumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease［J］. Neurobiol Aging， 2004， 25 （3）： 283-290.

YANG S P， KWON B O， GHO Y S， et al ， Specific interaction of VEGF165 with beta-amyloid， and its protective effect on beta-amyloid-induced neurotoxicity［J］. J Neurochem， 2005， 93 （1）： 118-127.

张玲，褚扬，马晓慧，等.养血清脑颗粒的药理作用研究进展［J］.医学综述，2011，17（5）：769-771.

WANG F， HU Q， CHEN C H， et al. The protective effect of cerebralcare granule； on brain edema， cerebral micro circulatory disturbance，and neuron injury in a focal cerebral ischemia rat model［J］. Microcirculation， 2012， 19（3）： 260-272.

QU Z， ZHANG J， GAO W， et al. Vasorelaxant effects of cerebralcare granule are mediated by NO/cGMP pathway， potassium channel opening and calcium channel blockade in isolated rat thoracic aorta ［J］．J Ethnopharmacol， 2014， 155 （1）： 572-579.

叶海森，陈曦，李韧娇，等.养血清脑颗粒对认知功能障碍大鼠学习、记忆及GAP-43、PSD-95表达的影响［J］.世界中医药，2020，15（7）：1021-1024.

吕佩源，台立稳，段瑞生，等.养血清脑颗粒治疗轻中度血管性认知障碍患者多中心研究［J］.中华行为医学与脑科学杂志，2018，27（5）：405-410.

赵瑾，周华东，张涛，等.养血清脑颗粒治疗老年性痴呆60例临床观察［J］.重庆医学，2007，36（22）：2313-2314.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Gualou Xiebai Banxiatang on Myocardial Microangiogenesis and HIF-1α/VEGF-related Pathways in Myocardial Ischemia Model Rats

Effect of Jianpi Bushen Huoxue Prescription on Rat Brain Microvascular Endothelial Cells Based on HIF-1α/VEGF Signaling Pathway

Role of MAPK Signaling Pathway in Prevention and Treatment of Rheumatoid Arthritis and Chinese Medicine Intervention： A Review

Protective Effect of Jianpi Huogu Prescription on Functional Injury of Vascular Endothelial Cells Caused by Alcohol Based on Akt/JNK/p38 MAPK Signaling Pathway

Mechanism of Dihuang Yinzi in Improving Astrocyte Injury and Glycolysis in AD Mice via PI3K/Akt Pathway

Related Author

CHEN Wenhao

MENG Weishan

LI Hong

TIAN Weiwei

ZHANG Qi

TAN Yingying

LIU Xuenan

LIU Xiangzhe

Related Institution

The Second Affiliated Hospital of Henan University of Science and Technology

Basic Medical College，Shaanxi University of Chinese Medicine

Nanyang Nanshi Hospital

The First Affiliated Hospital of Henan University of Chinese Medicine

Gansu University of Chinese Medicine

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰